☆ 4.5 Letter

Dupilumab in adolescents with moderate to severe atopic dermatitis: a 32-week real-world experience during the COVID-19 pandemic

CLINICAL AND EXPERIMENTAL DERMATOLOGY (2022)

Journal

CLINICAL AND EXPERIMENTAL DERMATOLOGY

Volume 47, Issue 1, Pages 165-167

Publisher

WILEY

DOI: 10.1111/ced.14862

Keywords

-

Categories

Dermatology

Ask authors/readers for more resources

Protocol

Community support

Reagent

Community support

Authors

I am an author on this paper

Click your name to claim this paper and add it to your profile.

Reviews

Primary Rating

4.5

Not enough ratings

Secondary Ratings

Novelty

-

Significance

-

Scientific rigor

-

Rate this paper

Recommended

No Data Available

No Data Available

No Data Available

© Peeref 2019-2024. All rights reserved.